Allogene therapeutics moves forward with standard fludarabine and cyclophosphamide (fc) lymphodepletion regimen in the alpha3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large b-cell lymphoma

South san francisco, calif., aug. 01, 2025 (globe newswire) -- allogene therapeutics, inc. (nasdaq: allo), a clinical-stage biotechnology company pioneering the development of allogeneic car t (allocar t™) products for cancer and autoimmune disease, today announced that it has selected standard fludarabine and cyclophosphamide (fc) as the lymphodepletion regimen to be used in its alpha3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large b-cell lymphoma (lbcl). this lymphodepletion regimen selection was made in conjunction with the alpha3 data and safety monitoring board (dsmb) and steering committee and following consultation with the u.s. food and drug administration (fda).
FC Ratings Summary
FC Quant Ranking